Snowdrift Parent Corporation earnings releases CMMB

Annual Quarterly

Snowdrift Parent Corporation last reported quarterly results on May 11, 2023, for Q1 FY2023 (the quarter ended Mar 31, 2023): diluted EPS of $0.04. It usually reports 41–52 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 41–52 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released	Quarter	Revenue	Net income	Diluted EPS
May 11, 2023 41 days after quarter end	Q1 FY2023 ended Mar 31, 2023	—	-9 -71.5%	0.04
Feb 21, 2023 52 days after quarter end	Q4 FY2022 ended Dec 31, 2022	—	-8 -64.3%	-0.04
Aug 12, 2022 43 days after quarter end	Q2 FY2022 ended Jun 30, 2022	—	-6 -123.5%	0.03
May 12, 2022 42 days after quarter end	Q1 FY2022 ended Mar 31, 2022	—	-5 -199.5%	—
Mar 9, 2022 68 days after quarter end	Q4 FY2021 ended Dec 31, 2021	—	-5 -158.1%	—
Nov 12, 2021 43 days after quarter end	Q3 FY2021 ended Sep 30, 2021	—	-3 -142.5%	—
Aug 13, 2021 44 days after quarter end	Q2 FY2021 ended Jun 30, 2021	—	-3 -156.2%	—
May 13, 2021 43 days after quarter end	— ended Mar 31, 2021	—	—	—

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: CMMB (Nasdaq)
Fiscal year ends: December 31
Incorporated in: Israel
Headquarters: Tel Aviv
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1534248
Former names: Anchiano Therapeutics Ltd. (until Mar 17, 2021); BioCancell Ltd. (until Nov 3, 2015)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.